

The Honorable Gary LeBeau, Senator
The Honorable Chris Perone, State Representative
Commerce Committee
General Assembly
Room 110, Capitol Building
Hartford, CT 06106

March 18, 2014

RE: IN SUPPORT OF Bill 5574

***AN ACT IMPLEMENTING THE RECOMMENDATIONS OF THE
SOUTHEASTERN CONNECTICUT BIOSCIENCE CAPABILITIES
ASSESSMENT REPORT***

Dear Co-Chairmen LeBeau and Perone:

I support Bill 5547, to establish and administer a program to promote and support the development of bioscience and biotechnology businesses in the Southeastern Connecticut Planning Region. I believe that this bill can be a vehicle to augment Connecticut's commitment to strengthen the bioscience/ biotechnology presence and prominence in the State.

I am currently an independent pharmaceutical consultant through my sole proprietorship, *Pharma Regulatory Connection*, who resides in Waterford. I am an active member of SECTen, Eastern CT Chamber of Commerce and CURE. My career has consisted of many years working for large pharmaceutical companies (BMS, Abbott Laboratories and Bayer), followed by leadership roles at Alexion, Rib-X and most recently, New Haven Pharmaceuticals (NHP). I was responsible for the marketing approval of Alexion's first product, Soliris, in both the US (2007) and EU (2007), while serving on the company's Management Team. Among my clients, I assisted founder Harry Penner, and later CEO Patrick Forteau, in the startup and funding (Series A and B) of New Haven Pharmaceuticals, and have been acting as their VP of Regulatory Affairs for the last 5 years. NHP will be submitting their first NDA to FDA in 2014 for marketing approval of their first product, for a cardiovascular indication. Approval and launch are expected in 2015.

Because of my background and experience, I am well aware of the need for, and value of, an organized, connected and engaged bioscience community in Southeastern CT. As outlined in the Southeastern CT Bioscience Capabilities Assessment Report, there

exists much talent in the region, and there is much business activity currently underway. What is lacking is an organization that would facilitate interaction internally/regionally among this talent pool and business and business service providers, as well as externally, with other regions of the state (such as the New Haven, Farmington and Stamford organizations), organizations such as CURE, other states and beyond.

Connecticut is poised for and committed to national excellence and leadership in the bioscience/biotechnology space. This commitment requires full and equal accessibility and participation by all of the State's regions. By strengthening the organization in Southeastern CT we will be helping the State to realize this goal.

For the reasons stated in this testimony, I hope that you will agree with me that the proposals put forth in Bill 5574 are worthy of approval and implementation.

Thank you for your consideration.

Kind regards,

Nancy C. Motola, PhD, RAC
Principal Consultant, Pharma Regulatory Connection

CC: The Honorable Elizabeth Ritter